Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 4/20 | 0.68 |
| ▸ | CTSL | P07711 | 2/20 | 0.66 |
| ▸ | CTSS | P25774 | 1/20 | 0.66 |
| ▸ | CTSK | P43235 | 1/20 | 0.66 |
| ▸ | MAPT | P10636 | 2/20 | 0.61 |
| ▸ | TP53 | P04637 | 1/20 | 0.61 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.60 |
| ▸ | CCKBR | P32239 | 6/20 | 0.60 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.60 |
| ▸ | TACR1 | P25103 | 2/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27787321 | 1.00 | ACE (0.68) | ACECTSLCTSSCTSKMAPT | |
| SCHEMBL645234 | 1.00 | ACE (0.68) | ACECTSLCTSSCTSKMAPT | |
| SCHEMBL30608293 | 0.96 | CTSL (0.69) | ACECTSLCTSSCTSKMAPT | |
| SCHEMBL645235 | 0.93 | ACE (0.66) | ACECTSLCTSSCTSKMAPT | |
| SCHEMBL27885283 | 0.93 | ACE (0.66) | ACECTSLCTSSCTSKMAPT | |
| SCHEMBL27885284 | 0.93 | ACE (0.66) | ACECTSLCTSSCTSKMAPT | |
| SCHEMBL27871524 | 0.92 | CTSL (0.76) | ACECTSLCTSSCTSKMAPT | |
| SCHEMBL27902245 | 0.92 | CTSL (0.76) | ACECTSLCTSSCTSKMAPT | |
| SCHEMBL6424722 | 0.92 | CTSL (0.68) | ACECTSLCTSSCTSKMAPT | |
| SCHEMBL6429159 | 0.92 | CTSL (0.68) | ACECTSLCTSSCTSKMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103288705-A | Crystalline d-isoglutamyl-d-tryptophan and the mono ammonium slat of d-isoglutamyl-d-tryptophan | APOTEX TECHNOLOGIES INC | 2013-09-11 | — | — | CN | disclosed |
| CN-103288704-A | Crystalline d-isoglutamyl-d-tryptophan and the mono ammonium slat of d-isoglutamyl-d-tryptophan | APOTEX TECHNOLOGIES INC | 2013-09-11 | — | — | CN | disclosed |
| CN-103288706-A | Crystalline d-isoglutamyl-d-tryptophan and the mono ammonium slat of d-isoglutamyl-d-tryptophan | APOTEX TECHNOLOGIES INC | 2013-09-11 | — | — | CN | disclosed |
| WO-2013123574-A1 | ORALLY BIOAVAILABLE DERIVATIVES OF D-GAMMA-GLUTAMYL-D-TRYPTOPHAN | APOTEX TECHNOLOGIES INC. (CA) | 2013-08-29 | — | — | WO | disclosed |
| US-8507449-B2 | Crystalline D-isoglutamyl-D-tryptophan and the mono ammonium salt of D-isoglutamyl-D-tryptophan | APOTEX TECHNOLOGIES INC. (CA) | 2013-08-13 | — | — | US | disclosed |
| US-8476235-B2 | Crystalline D-isoglutamyl-D-tryptophan and the mono ammonium salt of D-isoglutamyl-D-tryptophan | APOTEX TECHNOLOGIES INC. (CA) | 2013-07-02 | — | — | US | disclosed |
| US-20130059791-A1 | CRYSTALLINE D-ISOGLUTAMYL-D-TRYPTOPHAN AND THE MONO AMMONIUM SLAT OF D-ISOGLUTAMYL-D-TRYPTOPHAN | APOTEX TECHNOLOGIES INC. (CA) | 2013-03-07 | — | — | US | disclosed |
| US-20130060048-A1 | CRYSTALLINE D-ISOGLUTAMYL-D-TRYPTOPHAN AND THE MONO AMMONIUM SLAT OF D-ISOGLUTAMYL-D-TRYPTOPHAN | APOTEX TECHNOLOGIES INC. (CA) | 2013-03-07 | — | — | US | disclosed |
| US-20120157387-A1 | ORALLY BIOAVAILABLE D-GAMMA-GLUTAMYL-D-TRYPTOPHAN | APOTEX TECHNOLOGIES INC. (CA) | 2012-06-21 | — | — | US | disclosed |
| US-8119606-B2 | Crystalline D-isoglutamyl-D-tryptophan and the mono ammonium salt of D-isoglutamyl-D-tryptophan | Apotex Technologies (CA) | 2012-02-21 | — | — | US | disclosed |
| US-20100016243-A1 | CRYSTALLINE D-ISOGLUTAMYL-D-TRYPTOPHAN AND THE MONO AMMONIUM SALT OF D-ISOGLUTAMYL-D-TRYPTOPHAN | APOTEX TECHNOLOGIES INC. (CA) | 2010-01-21 | — | — | US | disclosed |
| CN-101605806-A | Crystalline D-isoglutamyl-D-tryptophan and the mono ammonium salt of D-isoglutamyl-D-tryptophan | APOTEX TECHNOLOGIES INC (CA) | 2009-12-16 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130060048-A1 | CRYSTALLINE D-ISOGLUTAMYL-D-TRYPTOPHAN AND THE MONO AMMONIUM SLAT OF D-ISOGLUTAMYL-D-TRYPTOPHAN | AADAT, DLST, HTT | ACE 828/4885CTSL 1553/4885CTSS 2546/4885 |
| US-20100016243-A1 | CRYSTALLINE D-ISOGLUTAMYL-D-TRYPTOPHAN AND THE MONO AMMONIUM SALT OF D-ISOGLUTAMYL-D-TRYPTOPHAN | DDC, AADAT, GLUL | ACE 381/4885CTSL 1145/4885CTSS 1860/4885 |
| US-20120157387-A1 | ORALLY BIOAVAILABLE D-GAMMA-GLUTAMYL-D-TRYPTOPHAN | TPH1, TPH2, GLUL | ACE 833/4885CTSL 373/4885CTSS 783/4885 |
| US-20130059791-A1 | CRYSTALLINE D-ISOGLUTAMYL-D-TRYPTOPHAN AND THE MONO AMMONIUM SLAT OF D-ISOGLUTAMYL-D-TRYPTOPHAN | AADAT, DLST, HTT | ACE 828/4885CTSL 1553/4885CTSS 2546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.